Maurizio Mangolini

Maurizio Mangolini

Auto-generated profile, based on publicly available information

Maurizio Mangolini

Wellcome Trust/MRC Cambridge Stem Cell Institute & Department of Haematology, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JEJoy Edwards-Hicks
Joy Edwards-Hicks
HSHuizhong Su
Huizhong Su
MMMaurizio Mangolini
Maurizio Mangolini
KYKubra K. Yoneten
Kubra K. Yoneten
JWJimi Wills
Jimi Wills
Andy FinchAndy Finch
Andy Finch
The MYC oncogene is a potent driver of growth and proliferation but also sensitises cells to apoptosis, which limits its oncogenic potential. MYC induces several biosynthetic programmes and primary cells overexpressing MYC are highly sensitive to glutamine withdrawal suggesting that MYC-induced sensitisation to apoptosis may be due to imbalance of metabolic/energetic supply and demand. Here we show that MYC elevates global transcription and translation, even in the absence of glutamine, revealing metabolic demand without corresponding supply. Glutamine withdrawal from MRC-5 fibroblasts depletes key tricarboxylic acid (TCA) cycle metabolites and, in combination with MYC activation, leads to AMP accumulation and nucleotide catabolism indicative of energetic stress. Further analyses reveal that glutamine supports viability through TCA cycle energetics rather than asparagine biosynthesis and that TCA cycle inhibition confers tumour suppression on MYC-driven lymphoma in vivo. In summary, glutamine supports the viability of MYC-overexpressing cells through an energetic rather than a biosynthetic mechanism.

15 January 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
EPEugene Park
Eugene Park
JCJingyu Chen
Jingyu Chen
AMAndrew Moore
Andrew Moore
MMMaurizio Mangolini
Maurizio Mangolini
ASAntonella Santoro
Antonella Santoro
IRIngo Ringshausen
Ingo Ringshausen
Overcoming drug resistance remains a key challenge to cure patients with acute and chronic B cell malignancies. Here, we describe a stromal cell–autonomous signaling pathway, which contributes to drug resistance of malignant B cells. We show that protein kinase C (PKC)–β–dependent signals from bone marrow–derived stromal cells markedly decrease the efficacy of cytotoxic therapies. Conversely, small-molecule PKC-β inhibitors antagonize prosurvival signals from stromal cells and sensitize tumor cells to targeted and nontargeted chemotherapy, resulting in enhanced cytotoxicity and prolonged survival in vivo. Mechanistically, stromal PKC-β controls the expression of adhesion and matrix proteins, required for activation of phosphoinositide 3-kinases (PI3Ks) and the extracellular signal–regulated kinase (ERK)–mediated stabilization of B cell lymphoma–extra large (BCL-XL) in tumor cells. Central to the stroma-mediated drug resistance is the PKC-β–dependent activation of transcription factor EB, regulating lysosome biogenesis and plasma membrane integrity. Stroma-directed therapies, enabled by direct inhibition of PKC-β, enhance the effectiveness of many antileukemic therapies.

11 September 2020 in HemaSphere
Verified
Journal Article
Open access
CVClemence Virely
Clemence Virely
LGLuca Gasparoli
Luca Gasparoli
MMMaurizio Mangolini
Maurizio Mangolini
KCKatherine Clesham
Katherine Clesham
SISarah Inglott
Sarah Inglott
OWOwen Williams
Owen Williams
Supplemental Digital Content is available in the text